Eaton Corporation plc vs 10X Genomics Inc — how do they compare? Eaton Corporation plc trades at $463.63 (market cap $172.82B), while 10X Genomics Inc trades at $57.06 (market cap $7.61B). The key difference: Eaton Corporation plc is far larger — about 22.7× 10X Genomics Inc's market cap, and Eaton Corporation plc pays a 0.99% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| ETN | TXG | |
|---|---|---|
Market Cap | $172.82B | $7.61B |
Sector | Technology | Health |
52-Week High | $459.29 | $58.57 |
52-Week Low | $315.82 | $11.34 |
Enterprise Value | $193.45B | $7.14B |
Dividend Yield | 0.99% | — |
Signals from Pluang's Aura AI — not financial advice
Eaton Corporation (ETN) trades at $468.37, up 5.26% in 24 hours, reflecting strong momentum after recent earnings beats. The stock exhibits a bullish technical trend with support at $456 and resistance at $470. Q2 2026 earnings beat expectations with EPS of $3.15 versus $3.07 estimated, and the company raised its full-year outlook, driven by robust demand in electrical and data center segments.
Outlook remains positive given raised guidance and AI-driven power infrastructure demand, but risks include premium valuation (P/E 45.31) and execution challenges. Analyst consensus is bullish with a $499.75 price target, though investors should monitor competitive pressures and macroeconomic conditions affecting industrial spending.
TXG trades at $58.57, up 12.57% in 24 hours, reflecting strong momentum. The stock is technically bullish with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and revenue growth, yet remains unprofitable with a negative net income margin. Recent news highlights collaborations and acquisitions expanding its genomic capabilities.
Outlook is mixed; analyst consensus is neutral with a $46 price target below current levels, indicating caution despite recent beats. Key risks include sustained losses and competitive pressures, but operational cash flow growth and strategic expansions offer potential upside for patient investors focused on long-term biotech innovation.
Trailing returns across standard periods
Latest headlines on both assets
Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.
Read more on ETN →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →